Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hong Kong Pharma Digital Technology Holdings Ltd. ( (HKPD) ) has provided an update.
At its annual general meeting on December 12, 2025, Cellyan Biotechnology Co., Ltd. (formerly Hong Kong Pharma Digital Technology Holdings Limited) secured shareholder approval to significantly increase its authorized share capital from 100 million to 1 billion ordinary shares and to reclassify this capital into 940 million Class A ordinary shares and 60 million Class B ordinary shares, each with a par value of US$0.001. Shareholders also approved a corporate rebranding, with the English name changed to Cellyan Biotechnology Co., Ltd. and a new Chinese dual foreign name adopted, effective upon issuance of a Certificate of Incorporation on Change of Name by the Cayman Islands Registrar on December 19, 2025, and the adoption of a Fourth Amended and Restated Memorandum and Articles of Association, collectively signaling a strategic restructuring of the company’s capital structure and governance framework that may support future financing flexibility and clarify its identity as a biotechnology player.
More about Hong Kong Pharma Digital Technology Holdings Ltd.
Cellyan Biotechnology Co., Ltd., formerly Hong Kong Pharma Digital Technology Holdings Limited, is a Cayman Islands–incorporated company in the biotechnology and pharmaceutical-related sector. The company is listed in the United States as a foreign private issuer and operates from Hong Kong, positioning itself within the broader life sciences and pharma technology market.
Average Trading Volume: 160,863
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.79M
See more data about HKPD stock on TipRanks’ Stock Analysis page.